- Home
- SGP vs AUTL Comparison
SGP vs AUTL Comparison
Compare SGP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | AUTL |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United Kingdom |
| Employees | 65 | 752 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 650.9M | 532.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | SGP | AUTL |
|---|---|---|
| Price | $25.09 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $45.00 | $8.50 |
| AVG Volume (30 Days) | 97.2K | ★ 1.9M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $17.06 | $1.18 |
| 52 Week High | $30.56 | $2.52 |
Technical Indicators
Market Signals| Indicator | SGP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 68.69 | 70.85 |
| Support Level | $20.95 | $1.31 |
| Resistance Level | $25.83 | $2.07 |
| Average True Range (ATR) | 1.34 | 0.13 |
| MACD | 0.38 | 0.06 |
| Stochastic Oscillator | 95.56 | 88.57 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.